SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: NotAsBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 5/28/2017 8:05:39 PM - Followers: 715 - Board type: Free - Posts Today: 61

Cellceutix Corporation (CTIX)
 

http://cellceutix.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com

 
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly-traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Cellceutix's psoriasis drug candidate Prurisol completed a Phase 2 trial and Cellceutix recently launched a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at www.cellceutix.com.

Management:  http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.cellceutix.com/therapeutic-areas/

 

PIPELINE:

 

FDA DESIGNATIONS:

 

COMPLETED/UPCOMING MILESTONES:



Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines
http://www.cellceutix.com/press-release/

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 
info@cellceutix.com

http://www.cellceutix.com/new-faq/


Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
CTIX News: Quarterly Report (10-q) 05/09/2017 04:09:09 PM
CTIX News: Amended Statement of Ownership (sc 13g/a) 04/28/2017 12:50:45 PM
CTIX News: Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance 04/17/2017 07:03:27 AM
CTIX News: Current Report Filing (8-k) 03/31/2017 04:25:24 PM
CTIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 03/29/2017 04:13:08 PM
PostSubject
#182860  Sticky Note B-UP Due Diligence (Rev. 5/22) sox040713 05/22/17 03:11:36 PM
#182459  Sticky Note Good NEWS...Cellceutix Completes Patient Enrollment of Final Cohort TheDane 05/18/17 09:40:08 AM
#180448  Sticky Note PART II *** Please Read DaubersUP 04/28/17 12:59:51 PM
#175709  Sticky Note CTIX Milestones, Clinical Trials, Recent Interviews, Fact Sheets sox040713 03/18/17 06:44:12 PM
#174938  Sticky Note B-UP Due Diligence (Rev. 3/10) sox040713 03/10/17 04:08:53 PM
#183525   But thank heavens a stage three trial is BioTechMaven 05/28/17 08:05:39 PM
#183524   reread my responses and hopefully it will register TheHound 05/28/17 07:58:45 PM
#183523   How do you know that he still works loanranger 05/28/17 07:55:37 PM
#183522   More or less. If one term -- scottsmith 05/28/17 07:54:42 PM
#183521   1984. BioTechMaven 05/28/17 07:50:06 PM
#183520   With your flawed logic we should call a BioTechMaven 05/28/17 07:49:18 PM
#183519   What i said in response to ur ? TheHound 05/28/17 07:35:15 PM
#183518   $CTIX - Both the Kevetrin Ovarian Cancer trial KarinCA 05/28/17 06:12:05 PM
#183517   Prurisol is a very potent inhibitor of IL-20 georgejjl 05/28/17 05:25:49 PM
#183516   "My premise is that K and UP aren't F1ash 05/28/17 03:34:24 PM
#183514   If you agree to the premise that Phase sox040713 05/28/17 03:31:35 PM
#183513   My premise is that K and UP aren't scottsmith 05/28/17 03:21:36 PM
#183512   At least my premise doesn't contain misinformation. Changing sox040713 05/28/17 03:18:33 PM
#183511   Interesting. Changing the premise of the original scottsmith 05/28/17 03:16:30 PM
#183510   If all three trials succeed and attract a sox040713 05/28/17 03:07:38 PM
#183507   CTIX has done a great job where it slcimmuno 05/28/17 02:57:29 PM
#183505   Lol! Are you serious? Jhawker 05/28/17 02:55:26 PM
#183503   Along with Mako shit pieces and attacks on alwaysdreaming 05/28/17 02:39:03 PM
#183502   "As stated in the filings, Dr. Alexander works loanranger 05/28/17 02:37:52 PM
#183501   • Phase 2a Trial of Brilacidin for UP/UPS (IBD) georgejjl 05/28/17 02:33:51 PM
#183500   I would have sworn that at one point scottsmith 05/28/17 02:28:14 PM
#183499   p and B, fingers crossed. Not sure JUST 10-11-12 05/28/17 02:25:48 PM
#183497   "Kevetrin is a 1b trial, no? " No "Phase 2" https://clinicaltrials.gov/ct2/s F1ash 05/28/17 02:17:15 PM
#183496   Kevtrin is P2a and so is B-UPS https://clinicaltrials.gov/ct2/show/NCT03042702 slcimmuno 05/28/17 02:15:03 PM
#183495   This study is designed as a randomized, double georgejjl 05/28/17 02:12:35 PM
#183494   Which one of the drugs in the Cellceutix georgejjl 05/28/17 02:08:09 PM
#183493   Kevetrin is a 1b trial, no? Maybe scottsmith 05/28/17 02:06:04 PM
#183491   why would think she's redundant? TheHound 05/28/17 01:56:53 PM
#183490   Thanks. I appreciate that there is a benefit loanranger 05/28/17 01:48:09 PM
#183489   So Jane Harness is redundant? Perhaps she scottsmith 05/28/17 01:32:23 PM
#183488   Sox040i13 Thank you. Echo20 Echo20 05/28/17 01:29:36 PM
#183487   As stated in the filings, Dr. Alexander works TheHound 05/28/17 01:26:58 PM
#183485   And more often than not imo that parsing slcimmuno 05/28/17 12:40:20 PM
#183484   I believe, that though many types of treatment F1ash 05/28/17 12:37:40 PM
#183482   That was a good explanation in February of loanranger 05/28/17 12:31:31 PM
#183481   "I have no idea how your question relates loanranger 05/28/17 12:28:37 PM
#183480   Here's the cite re competing trials slcimmuno 05/28/17 12:26:43 PM
#183479   I appreciate that you're trying to help and loanranger 05/28/17 12:11:23 PM
#183478   forgot the share price associated with this compound JUST 10-11-12 05/28/17 11:25:18 AM
#183477   How does Kevetrin relate to ABT-263? petemantx 05/28/17 10:06:46 AM
#183476   Like I said 6 months ago...... runninggirl2016 05/28/17 09:51:51 AM
#183475   Seems to me we ought to be able stevo99 05/28/17 09:46:35 AM
#183474   Important Safety Information *The safety and efficacy of Kepivance® thefamilyman 05/28/17 09:37:30 AM
#183473   I have no idea how your question relates NotAsBigKahuna 05/28/17 08:49:18 AM
#183472   I believe the July conference will be very Jhawker 05/28/17 08:48:37 AM
#183471   Lots of reasons why trials can take longer slcimmuno 05/28/17 08:41:35 AM
#183470   What's the main reason, if there is one, loanranger 05/28/17 07:36:57 AM
#183469   Do you think the research would apply and brucethepotter 05/28/17 07:02:11 AM
#183468   PolyCide® Antimicrobial Biomaterials run256 05/28/17 03:52:25 AM
#183467   Other areas. run256 05/28/17 03:49:43 AM
PostSubject